Learned intermediary doctrine

What is the learned intermediary doctrine?

The learned intermediary doctrine holds that a prescription drug or medical device manufacturer satisfies its duty to warn by adequately informing the prescribing physician, rather than the patient directly.

The reasoning is that physicians are positioned to evaluate risks against a specific patient's circumstances in a way a general consumer warning cannot.

It applies specifically to products requiring a prescription, and it changes how a failure to warn claim is built in these cases.

It is one of the most consequential doctrines in pharmaceutical litigation, since it redirects the entire warning claim toward a different audience.

How does this change a claim?

The focus shifts from what the patient was told to what the physician was told.

• The manufacturer's duty runs primarily to the prescribing physician
• Physician package inserts and prescribing information become central evidence
• Causation requires showing the physician would have acted differently with adequate warning
• The patient's own knowledge of the risk becomes less central to the analysis
• Sales representative communications with the prescriber are frequently relevant

What is the direct-to-consumer advertising qualification?

New Jersey has recognized an important consideration where a manufacturer advertises a prescription product directly to consumers.

Where direct marketing bypasses the physician's independent role in the decision, treating the physician as the sole necessary recipient of warnings may not fully address how the decision was actually made.

This has become more significant as direct-to-consumer pharmaceutical advertising has expanded considerably.

How this qualification applies depends heavily on the specific marketing involved and the circumstances of the prescribing decision.

How is causation proven under this doctrine?

By showing that adequate warning to the physician would have changed the prescribing decision, generally through the physician's own testimony about what they would have done with different information.

Some but not all courts also inquire into what the patient would have decided if warned directly, particularly where the marketing bypassed physician judgment.

This is why the treating physician's deposition is frequently the single most important piece of evidence in a case governed by this doctrine.

Prescribing patterns for other similar patients sometimes provide corroborating evidence about how the physician would likely have responded.

Common questions

Does this doctrine mean I cannot sue the manufacturer?

No. It changes who the warning had to reach and how causation is proven, but a viable claim can still exist based on what the physician was or was not told.

Does direct-to-consumer advertising change the analysis?

New Jersey has recognized this can be a relevant consideration. How it applies depends on the specific marketing and circumstances involved.

What if my doctor was never actually shown the warning?

That is a central question in these cases. What the prescriber actually received and reviewed, versus what the manufacturer provided, is examined closely.